XML 29 R14.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity
12 Months Ended
Dec. 31, 2016
Stockholders' Equity  
Stockholders' Equity

7. Stockholders’ Equity

In 2005, we adopted the 2005 Stock Option and Incentive Plan (2005 Plan) that authorizes us to grant options, restricted stock and other equity-based awards. As of December 31, 2016, 430,922 options to purchase shares of common stock were outstanding pursuant to grants in connection with the 2005 Plan.  No additional shares are available for issuance under the 2005 Plan.  The amount, terms of grants, and exercisability provisions are determined and set by our board of directors.

 

Effective August 2014, we adopted our 2014 Equity Incentive Plan (2014 Plan) that authorizes us to grant options, restricted stock, and other equity-based awards, subject to adjustment in accordance with the 2014 Plan.  As of December 31, 2016, 1,808,122 options to purchase shares of common stock and 195,900 restricted shares of common stock were outstanding pursuant to grants in connection with the 2014 Plan, and 31,922 shares of common stock were available for future issuance. The amount, terms of grants, and exercisability provisions are determined and set by our board of directors.  In accordance with the 2014 Plan, on January 1, 2017, shares of common stock available for future grants under the 2014 plan was increased to 820,127.

In August 2015, we entered into an Equity Distribution Agreement with JMP Securities LLC.  Subsequent to December 31, 2016 we sold 1,669,092 shares under this agreement for aggregate net proceeds of approximately $2.0 million.

Stock Options

Total compensation cost recognized for all stock option awards in the statements of operations is as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31,

 

 

 

2016

 

2015

 

2014

 

Research and development

    

$

980

    

$

685

    

$

137

    

General and administrative

 

 

1,975

 

 

1,423

 

 

561

 

Total

 

$

2,955

 

$

2,108

 

$

698

 

 

Options issued under both the 2005 Plan and 2014 Plan may have a contractual life of up to 10 years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than four years.  A summary of activity for the years ended December 31, 2016, 2015 and 2014 is presented below (in thousands, except share and per share amounts):

 

 

 

 

 

 

 

 

 

 

 

 

    

 

    

Weighted-

    

 

 

 

 

 

 

 

Average

 

Aggregate

 

 

 

 

 

Exercise Price

 

Intrinsic

 

 

 

Shares

 

Per Share

 

Value

 

Outstanding—December 31, 2013

 

1,093,208

 

$

1.04

 

 

 

 

Granted

 

700,000

 

 

8.99

 

 

 

 

Exercised

 

(122,634)

 

 

1.04

 

 

 

 

Outstanding—December 31, 2014

 

1,670,574

 

 

4.37

 

 

 

 

Granted

 

585,800

 

 

12.56

 

 

 

 

Exercised

 

(327,098)

 

 

1.14

 

 

 

 

Forfeited

 

(44,950)

 

 

6.13

 

 

 

 

Expired

 

(85,100)

 

 

1.04

 

 

 

 

Outstanding—December 31, 2015

 

1,799,226

 

 

7.74

 

 

 

 

Granted

 

603,975

 

 

2.42

 

 

 

 

Exercised

 

(118,365)

 

 

1.04

 

 

 

 

Forfeited

 

(45,792)

 

 

12.08

 

 

 

 

Outstanding—December 31, 2016

 

2,239,044

 

$

6.57

 

$

 —

 

 

 

 

 

 

 

 

 

 

 

Exercisable—December 31, 2016

 

1,182,966

 

$

6.96

 

$

 —

 

Exercisable and expected to vest—December 31, 2016

 

2,239,044

 

$

6.57

 

$

 —

 

 

The weighted average remaining contractual term of options outstanding and exercisable as of December 31, 2016 is 8.1 and 7.5 years, respectively.

Intrinsic value in the table above was determined by calculating the difference between the market value of our common stock on the last trading day of 2016 of $1.01 per share and the exercise price, multiplied by the number of in-the-money options. The aggregate intrinsic value as of December 31, 2016 was zero, because all outstanding options have exercise prices in excess of market value.  The aggregate intrinsic value of options exercised in 2016, 2015 and 2014 was $0.5 million, $3.4 million and $0.5 million, respectively.

The weighted‑average grant date fair value of options granted was $1.60, $8.15, and $6.09 per share in 2016, 2015 and 2014, respectively, and was estimated at the date of grant using the Black‑Scholes option‑pricing model with the following weighted‑average assumptions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

2016

    

    

2015

    

 

2014

 

Expected stock price volatility

 

74.69

-

87.67

%  

 

73.64

-

81.21

%  

 

77.66

-

86.08

%  

Expected term of options

 

5.2

-

6.1

years

 

5.2

-

6.1

years

 

5.5

-

6.06

years

Risk-free interest rate

 

1.07

-

1.86

%  

 

1.44

-

1.92

%  

 

1.75

-

1.98

%  

Expected annual dividend yield

 

 

 

0

%  

 

 

 

0

%  

 

 

 

0

%  

 

The weighted‑average valuation assumptions were determined as follows:

·

Expected stock price volatility: The expected volatility is based on historical volatilities of similar entities within our industry which were commensurate with our expected term assumption as described in the SEC’s Staff Accounting Bulletin, or SAB, No. 107.

·

Expected term of options: We estimated the expected term of our stock options with service‑based vesting using the “simplified” method, as prescribed in SAB No. 107, whereby the expected life equals the average of the vesting tranches and the original contractual term of the option due to our lack of sufficient historical data.

·

Risk‑free interest rate: We base the risk‑free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.

·

Expected annual dividend yield: The estimated annual dividend yield is 0% because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.

As of December 31, 2016, there was $4.2 million of total unrecognized compensation expense related to unvested stock options granted under the 2005 Plan and 2014 Plan. That expense is expected to be recognized over the next four years as follows, in thousands:

 

 

 

 

 

 

2017

    

$

2,473

2018

 

 

1,480

2019

 

 

242

2020

 

 

12

 

 

$

4,207

 

Restricted Stock

 

All issued and outstanding restricted shares of common stock are time-based and become vested one year after the grant date, pursuant to the 2014 Plan.  Compensation expense is recorded ratably over the requisite service period. Compensation expense related to restricted stock is measured based on the fair value using the closing market price of the Company’s common stock on the date of the grant.

 

No restricted shares of common stock were issued prior to fiscal year 2016.  A summary of activity for the year ended December 31, 2016 is presented below (in thousands, except share and per share amounts):

 

 

 

 

 

 

 

 

    

 

    

Weighted-average

 

 

 

 

Grant Date

 

 

Shares

 

Fair Value per Share

Outstanding—December 31, 2015

 

 —

 

$

 —

Granted

 

196,275

 

 

1.51

Vested

 

 —

 

 

 —

Forfeited

 

(375)

 

 

1.50

Outstanding—December 31, 2016

 

195,900

 

$

1.51

 

 

 

 

 

 

Expected to vest—December 31, 2016

 

195,900

 

$

1.51

 

As of December 31, 2016, there was $0.2 million of total unrecognized compensation cost related to unvested restricted stock is expected to be recognized over a weighted average service period of 0.59 years. 

 

Total compensation cost recognized for all restricted stock awards in the statements of operations for the year ended December 31, 2016 is as follows (in thousands):

 

 

 

 

 

 

Research and development

    

$

48

    

General and administrative

 

 

74

 

Total

 

$

122